Xilio Therapeutics/$XLO
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Xilio Therapeutics
Xilio Therapeutics Inc is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies (including bispecifics) and immune cell engagers (including tumor-activated cell engagers and tumor-activated effector-enhanced cell engagers).
Ticker
$XLO
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
64
ISIN
US98422T1007
Website
XLO Metrics
BasicAdvanced
$35M
-
-$0.83
-0.23
-
Price and volume
Market cap
$35M
Beta
-0.23
52-week high
$1.70
52-week low
$0.62
Average daily volume
2M
Financial strength
Current ratio
1.956
Quick ratio
1.912
Long term debt to equity
62.037
Total debt to equity
73.495
Interest coverage (TTM)
-569.57%
Profitability
EBITDA (TTM)
-55.259
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-585.54%
Operating margin (TTM)
-614.16%
Revenue per employee (TTM)
$140,000
Management effectiveness
Return on assets (TTM)
-38.21%
Return on equity (TTM)
-297.84%
Valuation
Price to revenue (TTM)
4.798
Price to book
3.3
Price to tangible book (TTM)
3.3
Price to free cash flow (TTM)
2.115
Free cash flow yield (TTM)
47.29%
Free cash flow per share (TTM)
32.27%
Growth
Earnings per share change (TTM)
-67.59%
3-year earnings per share growth (CAGR)
-49.74%
What the Analysts think about XLO
Analyst ratings (Buy, Hold, Sell) for Xilio Therapeutics stock.
XLO Financial Performance
Revenues and expenses
XLO Earnings Performance
Company profitability
XLO News
AllArticlesVideos
Xilio Therapeutics Appoints Akintunde Bello, Ph.D., to its Board of Directors
GlobeNewsWire·2 weeks ago
Xilio Therapeutics Announces Closing of $50.0 Million Public Offering
GlobeNewsWire·3 weeks ago
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewsWire·3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Xilio Therapeutics stock?
Xilio Therapeutics (XLO) has a market cap of $35M as of June 27, 2025.
What is the P/E ratio for Xilio Therapeutics stock?
The price to earnings (P/E) ratio for Xilio Therapeutics (XLO) stock is 0 as of June 27, 2025.
Does Xilio Therapeutics stock pay dividends?
No, Xilio Therapeutics (XLO) stock does not pay dividends to its shareholders as of June 27, 2025.
When is the next Xilio Therapeutics dividend payment date?
Xilio Therapeutics (XLO) stock does not pay dividends to its shareholders.
What is the beta indicator for Xilio Therapeutics?
Xilio Therapeutics (XLO) has a beta rating of -0.23. This means that it has an inverse relation to market volatility.